Jeewanjot Singh | Drug Discovery | Young Scientist Award

Published on by Young Scientists Awards

Young Scientist Award

Jeewanjot Singh
Researcher Jeewanjot Singh
Affiliation Desh Bhagat University
Country India
Scopus ID 59955293600
Documents 4
Citations 15
h-index 2
Subject Area Drug Discovery
Event International Young Scientists Award
ORCID 0009-0000-6290-9250

Jeewanjot Singh

Desh Bhagat University, India

Jeewanjot Singh is affiliated with Desh Bhagat University, India, and has developed an emerging academic profile in the interdisciplinary field of Drug Discovery. His published research contributes to the understanding of pharmaceutical sciences, medicinal chemistry, and modern approaches used in identifying and optimizing biologically active compounds. According to the available Scopus author metrics, the researcher has produced four indexed publications that have collectively received fifteen citations while maintaining an h-index of two, reflecting the early impact of his scholarly work within specialized research communities.[1]

Abstract

The academic profile of Jeewanjot Singh reflects an emerging contribution to drug discovery and pharmaceutical research through peer-reviewed publications indexed in international scientific databases. His research demonstrates interest in identifying therapeutic compounds, understanding biological mechanisms, and supporting evidence-based pharmaceutical innovation. Although still at an early stage of his research career, the available publication and citation indicators illustrate continuous scholarly engagement and growing international visibility. These achievements form an appropriate foundation for consideration within academic recognition programs that acknowledge promising young researchers.[1]

Keywords

Drug Discovery, Pharmaceutical Sciences, Medicinal Chemistry, Therapeutic Research, Scientific Publications, Scopus Author, Young Researcher, Biomedical Innovation, Research Excellence, International Young Scientists Award.

Introduction

Drug discovery represents one of the most demanding areas of biomedical research because it integrates chemistry, biology, pharmacology, computational science, and clinical knowledge. Researchers working in this discipline contribute to identifying novel therapeutic compounds, improving existing medicines, and addressing global health challenges through systematic scientific investigation. Early-career researchers play an important role in advancing innovative concepts and supporting collaborative research environments. The documented research activities of Jeewanjot Singh illustrate participation in this evolving scientific landscape through internationally indexed publications and measurable scholarly impact.[2]

Research Profile

Jeewanjot Singh is associated with Desh Bhagat University and maintains an internationally indexed Scopus author profile. His research portfolio currently includes four Scopus-indexed documents with fifteen citations and an h-index of two. These metrics indicate developing academic visibility and demonstrate that his publications have attracted attention from researchers working in related scientific disciplines. His ORCID profile further supports transparent researcher identification and facilitates international scholarly collaboration.[1]

Research Contributions

  • Contributed to research associated with modern drug discovery methodologies.
  • Participated in pharmaceutical and medicinal chemistry investigations.
  • Published peer-reviewed research indexed within Scopus.
  • Supported evidence-based scientific communication through internationally accessible publications.

Publications

The available bibliometric information indicates four indexed publications within the field of drug discovery and related pharmaceutical sciences. These publications contribute to the scientific literature through peer-reviewed dissemination and have collectively generated measurable citation activity. Publication records indexed in internationally recognized databases provide evidence of research quality, accessibility, and academic dissemination.[1]

Research Impact

Bibliometric indicators including citation counts and the h-index are widely used to evaluate scholarly influence alongside peer review and research quality. With fifteen citations and an h-index of two, Jeewanjot Singh demonstrates a developing research profile consistent with an emerging investigator. Continued publication activity, collaboration, and citation growth are expected to further strengthen the long-term academic impact of his research contributions.[3]

Award Suitability

Based on publicly available scholarly metrics, indexed publications, and active participation in pharmaceutical research, Jeewanjot Singh demonstrates characteristics commonly associated with emerging scientific excellence. His documented publication record, measurable citation performance, researcher identification through ORCID, and institutional affiliation collectively support eligibility for recognition programs that acknowledge promising early-career scientists. The International Young Scientists Award recognizes scholarly achievement, research quality, innovation, and professional development, making this academic profile relevant for consideration according to published award evaluation criteria.[4]

Conclusion

Jeewanjot Singh has established an emerging research presence within the field of drug discovery through internationally indexed publications and measurable citation performance. His academic activities demonstrate commitment to scientific investigation, knowledge dissemination, and continued professional development. As his publication portfolio expands, additional collaborations and research outputs are expected to further enhance his scholarly visibility. The current academic profile provides a structured overview suitable for institutional recognition, professional documentation, and consideration within international young researcher award programs.

References

  1. Elsevier. (n.d.). Scopus Author Details: Jeewanjot Singh, Author ID 59955293600.
    https://www.scopus.com/authid/detail.uri?authorId=59955293600
  2. Paul, S. et al. (2010). How to improve R&D productivity: the pharmaceutical industry’s grand challenge.
    DOI: https://doi.org/10.1038/nrd3078
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output.
    DOI: https://doi.org/10.1073/pnas.0507655102
  4. International Young Scientists Award. Award Information.
    https://youngscientistawards.com/

Pooja Kumari | Pharmaceutical Chemistry | Women Researcher Award

Published on by Young Scientists Awards

Ms. Pooja Kumari | Pharmaceutical Chemistry
| Women Researcher Award

JSS college of pharmacy, mysore | India

Ms. Pooja Kumari is an accomplished pharmaceutical researcher with over four years of experience in drug design, synthetic and medicinal chemistry, and scientific writing. She has expertise in computational approaches, including molecular docking, molecular dynamics simulation, QSAR, and homology modeling, alongside hands-on laboratory synthesis of novel compounds. Her Ph.D. research at JSS University focuses on designing and synthesizing novel purine derivatives as Aurora kinase-A inhibitors for breast cancer, integrating in-silico modeling with biochemical evaluation. She has contributed to medicinal chemistry through publications on pyrimidine, pyrazole, benzimidazole, and benzoxazole scaffolds, as well as reviews on pharmacogenomics and oncogenic signaling pathways, with 3 documents, 7 citations, and an h-index of 1. Pooja also has four years of teaching experience and practical guidance experience as a Research Assistant at SriramChem Laboratories. A registered pharmacist in India, she has completed workshops and certifications in AI-driven drug discovery and journal reviewing. Fluent in English and Hindi, she is currently enhancing her Dutch proficiency, reflecting adaptability and commitment to cross-cultural engagement. Her multidisciplinary expertise and strong analytical and communication skills enable her to contribute effectively in academic, research, and regulated pharmaceutical environments.

Profile: Orcid | Scopus 

Featured Publication

Kumari, P. (2026). Exploring pyrimidine scaffolds for cancer therapy: A triad of synthetic chemistry, computational studies, and in-vitro biological testing. Journal of Molecular Structure.

 

 

Syed Luqman Ali | Drug Design | Best Researcher Award

Published on by Young Scientists Awards

Mr. Syed Luqman Ali | Drug Design | Best Researcher Award

Researcher, Abdul Wali Khan University Mardan KPK Pakistan, Pakistan

Mr. Syed Luqman Ali is an enthusiastic researcher specializing in bioinformatics, computational biology, vaccine design, cancer, and drug development. Currently pursuing an MPhil in Biochemistry at Abdul Wali Khan University Mardan (2025), he has published extensively on vaccine and drug design using advanced computational techniques like RNA-seq, molecular docking, and simulation. Mr. Ali is a skilled reviewer for several high-impact journals and a lecturer at Metanoia College of Nursing. With expertise in bioinformatics tools and programming languages, he is committed to advancing scientific knowledge in vaccine and drug research.

Publication Profile

Google scholar

Education

Mr. Syed Luqman Ali is currently pursuing his MPhil in Biochemistry at Abdul Wali Khan University Mardan, Pakistan, with an expected graduation in 2025. He completed his Bachelor’s degree in Biochemistry from the same institution in 2022, laying the foundation for his research career. Additionally, he holds a Diploma in Digital Information Technology from the Board of Technical Education Peshawar, Pakistan, earned in 2021. This diverse educational background has equipped him with a strong interdisciplinary skill set, combining biochemistry, digital technology, and computational biology for cutting-edge research.

Research Experience

Mr. Syed Luqman Ali has been an Experimental and Computational Researcher at Abdul Wali Khan University Mardan since 2019. His research focuses on vaccine and drug design, utilizing advanced computational techniques like RNA-seq analysis, molecular docking, and simulation. With extensive experience in leading bioinformatics databases such as KEGG, MetaCyc, and HADDOCK, Mr. Ali is proficient in tools like SnapGene, Cytoscape, and DAVID. His work contributes to the development of innovative vaccines and drug therapies, advancing scientific knowledge in bioinformatics and computational biology.

Technical Certifications

Mr. Syed Luqman Ali has acquired several technical certifications that complement his research expertise. He completed a Data Analysis with R program through Mindluster, enhancing his data analysis skills. Additionally, he has obtained certifications in Data Analysis with Python and Linux from Udemy, further strengthening his computational abilities. Mr. Ali also completed a Content Writing course through the DigiSkills Training Program from Virtual University, Lahore, improving his communication and writing skills for scientific documentation. These certifications underscore his commitment to continuous learning and professional development in bioinformatics and computational biology.

Awards and Achievements

Mr. Syed Luqman Ali has made significant contributions to the scientific community, with multiple publications in high-impact journals, showcasing his research prowess in bioinformatics and computational biology. His work has been recognized by peers and researchers worldwide. Additionally, Mr. Ali serves as a reviewer for several reputed scientific journals, contributing his expertise to the advancement of research. These achievements reflect his dedication to scientific excellence and his active role in shaping future advancements in his field. 📚🖋️🔬

Research Focus

Mr. Syed Luqman Ali’s research spans multiple bioinformatics and computational biology domains, particularly in vaccine and drug design, cancer immunology, and genomics. His work includes multi-epitope vaccine development using immunoinformatics and reverse vaccinology approaches, along with genomic annotation for vaccine target identification. He has contributed significantly to disease diagnostics and drug discovery, especially in areas like tuberculosis, SARS-CoV-2, Leishmania, and autoimmune disorders. His expertise also extends to advanced data analysis, molecular docking, and RNA-seq analysis, employing tools like KEGG, MetaCyc, and HADDOCK. 🧬💻💉

Publication Top Notes

  • Mutational screening of GDAP1 in dysphonia associated with Charcot-Marie-Tooth disease: clinical insights and phenotypic effects
    Cited by: 20
    Year: 2023
  • Vaccinomics-based next-generation multi-epitope chimeric vaccine models prediction against Leishmania tropica – a hierarchical subtractive proteomics and …
    Cited by: 15
    Year: 2023
  • Genomic annotation for vaccine target identification and immunoinformatics-guided multi-epitope-based vaccine design against Songling virus through screening its whole genome …
    Cited by: 12
    Year: 2023
  • Currently trending and futuristic biological modalities in the management of different types of diabetes: A comprehensive review
    Cited by: 9
    Year: 2023
  • Analysis of the capability of IgG antibodies and receptors with their relationships to food tolerance and autoimmune disorders
    Cited by: 6
    Year: 2023
  • Illuminating the Frontier of Drug Discovery: Unleashing the Power of Bioinformatics for Unprecedented Breakthroughs
    Cited by: 4
    Year: 2023
  • Leveraging computer-aided design and artificial intelligence to develop a next-generation multi-epitope tuberculosis vaccine candidate
    Cited by: 1
    Year: 2024
  • Genetic identification and determination of parasites (Babesia, Leptospira and Toxoplasma Gondi) in wild rats
    Cited by: 1
    Year: 2024
  • Placental histology for targeted risk assessment of recurrent spontaneous preterm birth
    Cited by: 1
    Year: 2024
  • Harnessing bioinformatics for the development of a promising multi-epitope vaccine against tuberculosis: The ZL9810L vaccine
    Cited by: 1
    Year: 2024
  • Promising vaccine models against astrovirus MLB2 using integrated vaccinomics and immunoinformatics approaches
    Cited by: 1
    Year: 2024
  • Multi-epitope-based vaccine models prioritization against Astrovirus MLB1 using immunoinformatics and reverse vaccinology approaches
    Cited by: 1
    Year: 2025
  • Exploring advanced genomic and immunoinformatics techniques for identifying drug and vaccine targets against SARS-CoV-2
    Cited by: 1
    Year: 2024
  • A Comprehensive Methodological Review of Major Developments in Bioinformatics Pipelines for Transcriptomic Data Analysis
    Cited by: –
    Year: 2024
Conclusion

Mr. Ali’s solid academic background, innovative research contributions, advanced technical skills, and role as a mentor, he is undoubtedly a strong candidate for the Research for Best Researcher Award. His work in bioinformatics, drug design, vaccine development, and cancer research showcases his dedication to advancing scientific knowledge and making a global impact.